Articles from Levin Papantonio

A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because changes to a drug warning label are governed by federal law and the FDA. The pre-emption defence asserts that the FDA rejected its request to add a tumour warning to the drug’s label, pre-empting any state law claims that it failed to warn consumers and physicians. The plaintiffs argue that Pfizer’s pre-emption defence fails because the company’s request to the FDA was too broad, because it grouped Depo-Provera with other lower dose hormonal contraceptives, and this led to the FDA’s decision not to approve a tumour warning on the drug’s label in the USA. Also, according to a UN 2022 family planning report, 247 million worldwide are on hormonal contraceptives5,6.

LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- A new study published on 29 June 2025 in international peer-reviewed medical journal Expert Opinion on Drug Safety by Frey et al. (the Frey study) has found that use of depot medroxyprogesterone acetate (DMPA), which is manufactured by Pfizer Inc. (NYSE:PFE) and sold under the brand name Depo-Provera among others, for over one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma, a type of brain tumour, compared to the use of the combined birth control pill Ethinylestradiol/levonorgestrel (EE-LNG). The study used a database of 114 million unique individuals in its research. Expert Opinion on Drug Safety is an international subscription-based medical journal published by Informa4 publishing rigorously peer-reviewed articles on all aspects of drug safety.

A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States Courthouse is Pensacola, Florida. The litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer’s Depo-Provera (DMPA). One of the law firms appointed to the Plaintiff’s Executive Committee responsible for overseeing the MDL is Levin Papantonio, which has helped to secure more than $80 billion in jury verdicts and settlements against some of the world's largest corporations, including Johnson & Johnson, BP, Dupont, 3M, Merck and big tobacco. The law firm is currently acting for plaintiffs in the Talcum Powder Litigation against Johnson & Johnson and the Preterm Infant Nutrition Products Liability Litigation against Abbott Laboratories and Mead Johnson, owned by Reckitt Benckiser.